Why North Denmark?

North Denmark is the only region in Europe where basic and applied health science and technology research cooperate closely in a strategic alliance with the health sector (clinical research) and the business community.

North Denmark hosts several international clinical trial units which - together with researchers and clinical facilities - offer the region as one united clinical test site. With a population of approx. 600,000, most clinical trials on medical devices or pharmaceutical products can be performed on selected patient populations. 

Reasons to locate in North Denmark

• Advanced research at university and hospital

• International university environment

• Highly specialized university hospital

• A longstanding tradition for collaboration between business and research environments

• An innovative business and research environment

• Quick and easy access to established companies

• Quick and easy access to public organizations/institutions

• Educations in biomedical engineering, sport, biotechnology, and medicine

• Clusters of biomedical and ICT companies (Information and Communication Technology)

• A well-developed infrastructure

• Strong support from public authorities

• Attractive cost quality level

• Cheap real estate and accommodation

• Access to highly educated workforce

• Building sites and office space available for immediate industrial development

• International schools at all levels, a rich cultural life, safe city, and close to nature 

Facts about North Denmark

• Favorable incentive programs when investing in research

• Non-bureaucratic and very flexible labor market rules

• Competitive remuneration costs for employees with superior education and for management in general

• Aalborg University and the hospitals have a flexible approach to commercialization

• Aalborg University and the hospitals play an active role in protecting IPR (Intellectual Property Right)

• Attractive co-financing models between Aalborg University and industry 

Area

• 7,933 sq. km
• 18.4% of the total area of Denmark 

Population

• Approx. 600,000 inhabitants
• 11.3 % of the total Danish population 

Hospitals

The hospitals in North Denmark represent practically all medical specialties, and offer most types of treatment. The status of Aalborg Hospitals as a university hospital is of great importance to the high standard which the regional hospitals possess.

• 4 hospitals on 11 sites

• Approx. 1,800 beds

• Approx. 500,000 outpatients

• Approx. 1,344 clinicians in terms of man-year

• Approx. 3,940 nurses in terms of man-year 

Aalborg University

• Approx. 18,000 students

• Approx. 1,230 researchers

• Approx. 950 phd students 

Transparent and stable taxation system

• 25% corporate income tax – the lowest in Scandinavia

• Special tax scheme for foreign researchers and key employees: Flat tax rate of 26% over a period of 5 years

• Among the World´s lowest rates for employer-paid social insurances 

Denmark in general

• Financial stability and transparency

• The public sector is respected for its quality, its service mindedness and its positive approach to business

• Flexible labor market – most flexible hiring and firing regulations in Europe

• Qualified and motivated workforce – skilled labor ranked no. 1 in Europe

• Excellent language skills

• Access to entire the EU market place

• The best test market in the world

• International airports (incl. Aalborg)

• Dense and highly developed transportation infrastructure

• A major player and home to global pharmaceutical companies

• A strong and innovative medical technology industry

• Among the top 10 nations in the world when it comes to developing and applying new technology

• A unique interplay between universities and private companies on research

• Office rental costs and corporate taxes are the lowest in Scandinavia and generally below EU average

• Offers some of the world's lowest data and telecommunication rates

• Competitive salary levels for especially management/scientists

• Ranked no. 1 in the world on productivity of companies

• Fast and efficient approval of clinical trials